Podcasts by The MattCorc Podcast

Where does the market go from here? Will retail investors sell? from 2018-11-21T17:20:41

We talk about the recent market turmoil and how that will impact investor actions. Will investors stick to their guns or succumb and sell if the market continues to sell off. A few comments on Medt...

What’s the deal with GE? from 2018-11-16T15:03:35

GE has seen its market cap decrease by over $200B since 2016 and it now trades at around $8. Is this the correct value or should it be higher or perhaps lower?

We changed our name and Amazon announced their new locations! from 2018-11-14T21:47:22

Why we changed our name to the MattCorc Podcast. Who is taking the most risk with the Amazon headquarters, Amazon or the local/state government? What is Waymo? The first autonomous ride hailing ser...

A $500 Million Biotech IPO. Amarin Data from 2018-11-12T21:08:41

Moderna plans the biggest biotech IPO ever and we learn more about Amarin’s clinical study. Was mineral oil the best choice of placebo? Lessons we can learn from Amarin about D&O insurance.

Herd Mentality. Why D&O benchmarking is a sales ploy. What to use to make a more informed decision. from 2018-11-09T20:49:30

I talk about how brokers use benchmarking to sell you more D&O insurance. Brokers take advantage of herd mentality so insurers buy more D&O than they need.

Why cost should only be one consideration from 2018-11-06T21:27:56

Cost and its importance are discussed. Minor differences in coverage can cause major headaches when you have a claim.

S&P Companies not as negative; Gene Therapy manufacturing is stretched thin from 2018-11-05T18:28:07

Happy national doughnut day! Fewer companies in the S&P are providing negative guidance. What does this mean? How CFOs are protecting their balance sheets in the event their manufacturing is disrup...

Lessons from Halloween when your kids have peanut allergies from 2018-11-01T18:33:16

Why is Aimmune (AIMT) up today? Is it because Halloween reminded investors how many types of candy have peanuts in them? A lesson on how to make sure you aren’t missing significant coverage gaps in...

Swimming and the Dow Jones from 2018-10-29T21:22

How my first time swimming in a lap pool in years was a good metaphor for today’s market and some other interesting facts on the financial markets.

President’s Drug Pricing Speech and New CA Sexual Harassment Law from 2018-10-25T20:55:09

An overview of the President’s drug pricing proposal and what the new California sexual harassment law could mean for your insurance.

M&A Activity - Will Market Forces Play a Role? from 2018-10-24T20:58:23

With biotech stocks sinking, the XBI just hit a 52 week low, and interest rates rising will we see an urgency for acquisitions to be done?

Episode 36 - Concept or Concrete? from 2018-10-19T19:43:29

Quick post on why Insurance buying doesn’t need to be so abstract.

Episode 35 - McDermott Will & Emery Dealmaking Symposium Recap from 2018-10-18T20:40:08

A ton was learned at the MWE life science deal making symposium and here I share that with you.

Episode 34 - DeviceTalks Recap from 2018-10-17T19:55:27

A synopsis of DeviceTalks Boston. Pathways to acquisition, hurdles that you might face and how to derisk your company to make it more appealing to investors and acquiring companies.

Episode 33 - Chinese Espionage and Cyber Coverage from 2018-10-04T21:05:38

What can we learn from the alleged Chinese cyber espionage incident and how cyber insurance could respond.

Episode 32 - Can the Biotech IPO Market Sustain Itself? from 2018-10-03T20:28:41

I would love to hear whether people believe the pace of biotech IPOs will continue. Hear my thoughts and share yours at mattcorc.com.

I’m Doing an IPO and My D&O Insurance is Expensive from 2018-10-01T19:35:27

Why D&O Insurance is expensive for life science companies and how the stage your company is in impacts pricing.

FDA Condemns Undamaged Product - Insurance Should Have Paid from 2018-09-25T20:51:16

A client had a fire and $250,000 in product was destroyed. Undamaged condemned stock was valued at over $500,000 but there insurance did not cover it. Find out why that should never happen.

Episode 29 - MD Bio-Tech Conference Recap from 2018-09-21T14:16:11

A recap of the Maryland Bio-Tech Conference that I recently attended.

Episode 28 - NJTC CFO Forum Recap from 2018-09-19T21:02:25

A recap of the CFO Forum put on by the NJ Tech Council. The speaker was Jim Mastakas who was the CFO of Amneal when they merged with Impax Labs

Episode 27 - Monday Market Update from 2018-09-17T21:13:03

The impacts of Hurricane Florence on the property insurance market are discussed

Common Question Friday #1 from 2018-09-14T20:34:51

Why does a pre-clinical company need insurance?

Apple Watch, Transitioning From Digital Health to Med Device from 2018-09-13T21:04:37

A quick synopsis of how insurance liability changes as a company enters the realm to an FDA regulated product.

Hurricane Florence and Where to Look for Property Coverage from 2018-09-12T20:46:05

Where to look for additional coverage in your proprty policy above and beyond replacing your building or contents. Things to be aware of that could reduce coverage.

Abbvie Testosterone Settlement and Product Liability from 2018-09-11T17:15:10

I discuss the Abbvie testosterone settlement and the role of product liability insurance could play. Hurricanes and property insurance.

Episode 22 - Boston Biotech Week and RESI from 2018-09-10T15:09:13

A recap of Boston Biotech Week and the RESI conference. How insurance can help you stand out with investors.

Episode 21 - Patent Insurance...It’s a Real Thing from 2018-08-30T14:03:42

An overview of patent insurance and what it can do.

Episode 20 - Opioid Settlement and Product Liability from 2018-08-29T14:19:22

A discussion on Product Liability insurance in relation to a possible opioid settlement. Wage & Hour lawsuits are on the rise but there is a solution.

What happens when your supply chain is disrupted? from 2018-08-24T20:05:49

In the wake of an API manufacturer being shut down in China I discuss using insurance to mitigate the cash flow disruption.

Should Public Companies Only Report Earnings Semi-Annually? from 2018-08-23T20:43:19

The possible impacts on moving from quarterly to semiannual reporting periods for public companies on the D&O insurance marketplace

Episode 17 - Getting Your Product Approved from 2018-08-14T21:13:45

Amicus and Alnylam both got FDA approval last week. Find out how that can change their risk profile.

Cyber Insurance - Is Change Coming? from 2018-08-09T20:39:32

I discuss the PGA Championship being cyber extorted, CA Consumer Privacy Act and the role insurance plays in both of these events.

Apple, AIG, D&O Insurance and Patents from 2018-08-02T20:43:08

We discuss Apple hitting the $1 trillion mark, AIG going the other way, government taking your patent and D&O insurance

Episode 14 - Securities Class Action Filings and D&O Cover from 2018-07-31T20:38:10

I talk about the prevalence of securities class action filings and how D&O can protect you. I also discuss how we should not choose limits solely by what our peers have in place.

Episode 13 - Sarepta and Insuring Regulatory Risk from 2018-07-26T20:04:31

I talk about what we can learn from Sarepta's clinical hold and how they could insure such an event for their commercial product.

Episode 12 from 2018-07-25T20:23:18

Keryx Merger and Supply Chain issues from 2018-06-28T20:36:22

Today we are reminded, due to the news that Keryx and Akebia are merging, of what happens when you have a supply chain issue.

Insuring the Black Swan from 2018-06-27T21:42:06

Aquinox disaster and what you can do to protect your company from Black Swans.

Stryker Acquisition, CRISPR problems from 2018-06-11T20:53:38

Recap of today’s big events. Stryker bidding on Boston Scientific. CRISPR might cause cancer.

Liability for Digital Health Products from 2018-06-05T20:31:18

I discuss liability when a digital health product works but something bad happens. Blurring the lines of medtech and digital health.

Medtech Conference 2018 from 2018-06-04T18:30:58

A brief review of the 2018 Medtech conference in Minneapolis

Episode 6 - IPO and D&O from 2018-05-25T13:03:39

IPO market is healthy. Rockwell Medical and how D&O insurance could provide balance sheet protection

Episode 5 - Keytruda, Rockwell Medical, Spoilage from 2018-05-23T20:41:40

Keytruda does it again in the clinic and also changes to M&A landscape. What’s going on at Rockwell Medical? Is your product temperature sensitive?

Episode 4 - FDA and Hemophilia from 2018-05-22T21:24:47

Quick rundown on FDA related news, Hemophilia news and how right to try could impact the insurance market

May 17, 2018 from 2018-05-17T00:58:49

May 15, 2018 from 2018-05-15T21:58:36

May 11, 2018 from 2018-05-14T23:34:50

Episode 1 - Drug Pricing and Ford